SKYE BIOSCIENCE INC

SKYE is the ticker symbol for Skye Bioscience, Inc., a biopharmaceutical company. It trades on the Nasdaq Capital Market under the symbol SKYE. The company focuses on developing novel therapeutics, particularly in the areas of metabolic and inflammatory diseases. As a clinical-stage company, its stock is closely tied to research and development progress rather than commercial sales.

SKYE operates in the biotechnology and pharmaceutical industry. Specifically, it is a clinical-stage biopharma company focused on developing cannabinoid-based therapeutics and other novel drugs. This sector is characterized by high research costs, regulatory hurdles, and significant potential for volatility based on clinical trial outcomes. Investors often track SKYE alongside other small-cap biotech stocks.

Recent performance for SKYE stock is not provided here. For the latest price changes, historical trends, and percentage moves, please refer to the live SKYE stock data displayed on this page. That section will show up-to-date information on recent trading sessions, volume, and price range, which are essential for understanding current momentum.

Valuing SKYE requires different metrics than established companies because it is a clinical-stage biotech with likely no product revenue. Traditional metrics like P/E ratio may not apply. Instead, investors often consider cash runway, pipeline potential, and future market opportunities. For specific valuation data such as market cap or enterprise value, check the latest SKYE figures on this page.

To buy SKYE stock, you need a brokerage account that offers access to U.S. markets. Once your account is funded, you can place a buy order for SKYE shares through your broker's platform. Orders can be market or limit orders, depending on your preference. Ensure you understand your broker's fees and the current SKYE price before executing a trade.

Investing in SKYE carries significant risks common to clinical-stage biotech companies. These include the potential for disappointing clinical trial results, regulatory setbacks, and the need for additional capital, which can dilute existing shareholders. Additionally, SKYE's stock price can be highly volatile due to low trading volume and dependence on news flow. Investors should carefully review the company's risk factors in its SEC filings.